| Literature DB >> 21261918 |
Kou-San Ju1, Rebecca E Parales.
Abstract
Widespread application of chloronitrobenzenes as feedstocks for the production of industrial chemicals and pharmaceuticals has resulted in extensive environmental contamination with these toxic compounds, where they pose significant risks to the health of humans and wildlife. While biotreatment in general is an attractive solution for remediation, its effectiveness is limited with chloronitrobenzenes due to the small number of strains that can effectively mineralize these compounds and their ability to degrade only select isomers. To address this need, we created engineered strains with a novel degradation pathway that reduces the total number of steps required to convert chloronitrobenzenes into compounds of central metabolism. We examined the ability of 2-nitrotoluene 2,3-dioxygenase from Acidovorax sp. strain JS42, nitrobenzene 1,2-dioxygenase (NBDO) from Comamonas sp. strain JS765, as well as active-site mutants of NBDO to generate chlorocatechols from chloronitrobenzenes, and identified the most efficient enzymes. Introduction of the wild-type NBDO and the F293Q variant into Ralstonia sp. strain JS705, a strain carrying the modified ortho pathway for chlorocatechol metabolism, resulted in bacterial strains that were able to sustainably grow on all three chloronitrobenzene isomers without addition of co-substrates or co-inducers. These first-generation engineered strains demonstrate the utility of nitroarene dioxygenases in expanding the metabolic capabilities of bacteria and provide new options for improved biotreatment of chloronitrobenzene-contaminated sites.Entities:
Mesh:
Substances:
Year: 2009 PMID: 21261918 PMCID: PMC3815844 DOI: 10.1111/j.1751-7915.2008.00083.x
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 5.813
Figure 1Chloronitrobenzene degradation pathways previously characterized from bacterial isolates and co‐cultures. Asterisks (*) indicate steps that require the addition of a co‐substrate or co‐inducer in order to facilitate metabolite transformation.
Figure 2Possible reactions catalysed by nitroarene dioxygenases with CNBs. Solid black and white arrows indicate reactions detected by some or all of the nitroarene dioxygenases tested in this study. All of the reactions shown require NADH as a cofactor. Black arrows indicate reactions whose products are substrates for further metabolism by the modified ortho‐ring cleavage pathway (shown in Fig. 5). No evidence for the reactions indicated by dotted lines was obtained. 3ClCAT, 3‐chlorocatechol; 4ClCAT, 4‐chlorocatechol; 3NCAT, 3‐nitrocatechol; 4NCAT, 4‐nitrocatechol.
Figure 5Constructed pathways for CNB degradation in engineered Ralstonia sp. JS705 strains.
Relative ratios of products formed from CNBs by wild‐type and mutant nitroarene dioxygenases expressed in E. coli.
| Substrate | Dioxygenase | Catechols produced (% of total products) | |||
|---|---|---|---|---|---|
| 3ClCAT | 3NCAT | 4ClCAT | 4NCAT | ||
| 2CNB | NBDO | 97 ± 1 | 3 ± 1 | n/a | n/a |
| N258V | 88 ± 1 | 12 ± 1 | n/a | n/a | |
| F293H | 100 | – | n/a | n/a | |
| F293I | 100 | – | n/a | n/a | |
| F293Q | 100 | – | n/a | n/a | |
| I350F | 22 ± 3 | 78 ± 3 | n/a | n/a | |
| I350T | 85 ± 4 | 15 ± 4 | n/a | n/a | |
| 2NTDO | 98 ± 1 | 2 ± 1 | n/a | n/a | |
| 3CNB | NBDO | – | – | 100 | – |
| N258V | 1 ± 1 | – | 83 ± 1 | 16 ± 1 | |
| F293H | 100 | – | – | – | |
| F293I | – | – | 100 | – | |
| F293Q | – | – | 100 | – | |
| I350F | – | – | 100 | – | |
| I350T | – | – | 100 | – | |
| 2NTDO | – | – | 100 | – | |
| 4CNB | NBDO | n/a | n/a | 99 ± 0.4 | 1 ± 0.4 |
| N258V | n/a | n/a | 79 ± 4 | 21 ± 4 | |
| F293H | n/a | n/a | 100 | – | |
| F293I | n/a | n/a | 100 | – | |
| F293Q | n/a | n/a | 100 | – | |
| I350F | n/a | n/a | 66 ± 5 | 34 ± 5 | |
| I350T | n/a | n/a | 84 ± 0.3 | 16 ± 0.3 | |
| 2NTDO | n/a | n/a | 100 | – | |
3ClCAT, 3‐chlorocatechol; 4ClCAT, 4‐chlorocatechol; 3NCAT, 3‐nitrocatechol; 4NCAT, 4‐nitrocatechol; n = 3; n/a, not applicable, i.e. not a possible product from this substrate; –, none detected.
Figure 3Nitrite released from CNBs by E. coli strains expressing wild‐type and mutant nitroarene dioxygenases. 2CNB, white bars; 3CNB, grey bars; 4CNB, black bars. N = 3; error bars indicate standard deviations.
Doubling times and cell yields of engineered Ralstonia sp. JS705 strains.
| Substrate | Strain | Dioxygenase present | Doubling time | Maximum cell yield |
|---|---|---|---|---|
| 2CNB | JS705 (pKSJ99) | NBDO | 58.3 ± 3.5 | 0.18 ± 0.01 |
| JS705 (pKSJ114) | F293Q | 57.8 ± 2.7 | 0.31 ± 0.02 | |
| 3CNB | JS705 (pKSJ99) | NBDO | 26.0 ± 0.3 | 0.40 ± 0.02 |
| JS705 (pKSJ114) | F293Q | 20.0 ± 1.3 | 0.40 ± 0.02 | |
| 4CNB | JS705 (pKSJ99) | NBDO | 42.4 ± 3.7 | 0.27 ± 0.01 |
| JS705 (pKSJ114) | F293Q | 37.3 ± 0.3 | 0.24 ± 0.01 |
n = 2; ± indicate standard deviations. The control strain JS705 (pBBR1MCS2) did not grow on any of the CNBs.
Figure 4Growth and nitrite production from 3CNB by Ralstonia sp. JS705 derivatives. A. Growth on 3CNB. B. Nitrite released in culture supernatants. JS705(pBBR1MCS2), vector control, indicated by triangles; JS705(pKSJ99), expressing wild‐type NBDO, indicated by squares; and JS705(pKSJ114), expressing NBDO‐F293Q, indicated by circles. N = 2; error bars indicate standard deviations.
Bacterial strains and plasmids used in this study.
| Strain or plasmid | Relevant characteristics | Reference or source |
|---|---|---|
| DH5α | Cloning host; | Invitrogen |
| S17‐1 λ | Host for plasmid mobilization; | |
| Wild‐type toluene‐degrading strain | ||
| Wild‐type chlorobenzene‐degrading strain | ||
| Plasmids | ||
| pBBR1MCS2 | Broad‐host‐range vector; KmR | |
| pDTG800 | pUC18 containing | |
| pDTG850 | pUC13 containing | |
| pDTG927 | pUC19 containing | |
| pKSJ4 | pUC13 containing | |
| pKSJ10 | Derivative of pKSJ4, NBDO I350T expression plasmid; AmpR | |
| pKSJ12 | Derivative of pKSJ4, NBDO N258V expression plasmid; AmpR | |
| pKSJ19 | Derivative of pKSJ4, NBDO I350F expression plasmid; AmpR | |
| pKSJ21 | Derivative of pKSJ4, NBDO F293Q expression plasmid; AmpR | |
| pKSJ23 | Derivative of pKSJ4, NBDO F293I expression plasmid; AmpR | |
| pKSJ25 | Derivative of pKSJ4, NBDO F293H expression plasmid; AmpR | |
| pKSJ99 | pBBR1MCS2 containing | This study |
| pKSJ114 | Derivative of pKSJ99 containing | This study |
AmpR, ampicillin resistance; KmR, kanamycin resistance.